These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia. Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482 [TBL] [Abstract][Full Text] [Related]
5. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. Locatelli F; Algeri M; Merli P; Strocchio L Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013 [TBL] [Abstract][Full Text] [Related]
6. Concurrent juvenile myelomonocytic leukemia and T-lymphoblastic lymphoma with a shared missense mutation in NRAS. Ly B; Modi A; Rogers HJ; Makishima H; Hanna R; Cook JR; Theil KS; Maciejewski JP Pediatr Blood Cancer; 2014 May; 61(5):946-8. PubMed ID: 24610751 [TBL] [Abstract][Full Text] [Related]
7. Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. Raikar SS; Scarborough JD; Sabnis H; Bergsagel J; Wu D; Cooper TM; Keller FG; Wood BL; Bunting ST Pediatr Blood Cancer; 2016 Sep; 63(9):1667-70. PubMed ID: 27145535 [TBL] [Abstract][Full Text] [Related]
8. Juvenile myelomonocytic leukemia with t(3;5)(q25;q35), Auer rods and marked myelodysplasia. Li W; Cooley LD; August K Pathol Res Pract; 2018 Jun; 214(6):919-923. PubMed ID: 29496305 [TBL] [Abstract][Full Text] [Related]
9. JMML genomics and decisions. Niemeyer CM Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325 [TBL] [Abstract][Full Text] [Related]
10. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea. Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720 [TBL] [Abstract][Full Text] [Related]
11. After 95 years, it's time to eRASe JMML. Meynier S; Rieux-Laucat F Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238 [TBL] [Abstract][Full Text] [Related]
12. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia. Kraoua L; Journel H; Bonnet P; Amiel J; Pouvreau N; Baumann C; Verloes A; Cavé H Am J Med Genet A; 2012 Oct; 158A(10):2407-11. PubMed ID: 22887781 [TBL] [Abstract][Full Text] [Related]
13. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. Lasho T; Patnaik MM Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983 [TBL] [Abstract][Full Text] [Related]
14. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia. Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870 [TBL] [Abstract][Full Text] [Related]
15. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330 [TBL] [Abstract][Full Text] [Related]
16. Somatic mosaicism for a NRAS mutation associates with disparate clinical features in RAS-associated leukoproliferative disease: a report of two cases. Shiota M; Yang X; Kubokawa M; Morishima T; Tanaka K; Mikami M; Yoshida K; Kikuchi M; Izawa K; Nishikomori R; Okuno Y; Wang X; Sakaguchi H; Muramatsu H; Kojima S; Miyano S; Ogawa S; Takagi M; Hata D; Kanegane H J Clin Immunol; 2015 Jul; 35(5):454-8. PubMed ID: 25896945 [TBL] [Abstract][Full Text] [Related]
17. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment]. Sakashita K Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631 [TBL] [Abstract][Full Text] [Related]
18. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity. Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690 [TBL] [Abstract][Full Text] [Related]
19. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247 [TBL] [Abstract][Full Text] [Related]
20. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature. Ekvall S; Wilbe M; Dahlgren J; Legius E; van Haeringen A; Westphal O; Annerén G; Bondeson ML BMC Med Genet; 2015 Oct; 16():95. PubMed ID: 26467218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]